GlassScriptPhysician profile
Ofer N Sagiv
NPI 1689810491
$7,765.46
in general payments reported to CMS, 2019-2025
31 companies · $685 in 2025
The $685 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,317 · 2020: $821 · 2021: $502 · 2022: $1,897 · 2023: $1,446 · 2024: $1,097 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,228.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,753.88 | 2019-2024 | Jot Dx, Aveir, Cardiomems |
| Amgen INC. | $790.31 | 2019-2025 | Repatha, Repatha |
| Novo Nordisk INC | $660.27 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $607.75 | 2019-2024 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $556.34 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $510.69 | 2019-2025 | |
| Pfizer INC. | $481.02 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $409.62 | 2021-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $397.38 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $266.86 | 2021-2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $143.05 | 2020-2023 | Onpattro |
| Sanofi-Aventis U.S. LLC | $127.45 | 2019-2023 | |
| Heartflow, INC. | $118.31 | 2022-2024 | Ffrct |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $96.21 | 2019-2022 | |
| Lilly USA, LLC | $85.64 | 2022-2025 | Mounjaro |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $83.30 | 2019-2021 | |
| Lundbeck LLC | $79.13 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $74.81 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $70.69 | 2019 | |
| Esperion Therapeutics, INC. | $68.51 | 2020-2024 | Nexletol |
| Boston Scientific Corporation | $68.04 | 2019-2023 | Watchman Access System |
| Kiniksa Pharmaceuticals International, Plc | $62.96 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $55.89 | 2023-2024 | Inpefa |
| Philips North America LLC | $50.95 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Bayer Healthcare Pharmaceuticals INC. | $43.20 | 2025 | |
| Baxter Healthcare | $25.03 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Bardy Diagnostics, INC. | $17.30 | 2020 | |
| Vifor Pharma, INC. | $17.28 | 2019 | |
| Preventice Services, LLC | $16.91 | 2019 | |
| Astellas Pharma US INC | $13.65 | 2019 | |
| Biobeat USA INC. | $13.03 | 2024 | Bb-613 Bpm Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ofer Sagiv listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.